Vascular Ehlers-Danlos Syndrome (vEDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Vascular Ehlers-Danlos Syndrome (vEDS) Market Outlook

Thelansis’s “Vascular Ehlers-Danlos Syndrome (vEDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Vascular Ehlers-Danlos Syndrome (vEDS)   treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Vascular Ehlers-Danlos Syndrome (vEDS) Overview

Vascular Ehlers-Danlos Syndrome (vEDS) is an autosomal dominant condition; a child only has to inherit a defect in the COL3A1 gene from one parent to have the disorder. About half of people with vascular Ehlers-Danlos syndrome inherited the COL3A1 mutation from an affected parent. The other half of people with the condition have a spontaneous disease-causing mutation; that is, they are the first person in their family to have vascular Ehlers-Danlos syndrome. Each child of an affected parent has a 50% chance of inheriting the mutation and developing the disorder. The diagnosis of vascular Ehlers-Danlos syndrome is based on examining and identifying certain features and confirmation by laboratory testing. This testing may include DNA sequence analysis, deletion/duplication analysis, and biochemical (protein-based) testing. Genetic testing detects 98 percent of the changes in the gene for vascular Ehlers-Danlos syndrome; the rest require more specialized tests. Genetic testing is strongly recommended to confirm the vascular Ehlers-Danlos syndrome diagnosis when a person has a combination of any two of the major features of the condition, such as; Arterial rupture, Intestinal rupture, Uterine rupture during pregnancy, and Family history of vascular Ehlers-Danlos syndrome.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Vascular Ehlers-Danlos Syndrome (vEDS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034